Interim report January – September 2012
Continued positive sales development, +54% in the quarter and new distribution agreements in place for key markets.January – September 2012 · Global Net sales grew by 72% to SEK 110.8m (64.4). Adjusted for currency fluctuations, net sales rose by 69% Year over Year (Y-o-Y) · The worldwide number of NIOX MINO® repeat tests sold increased by 48% and for clinical use in the US grew by 68% · The loss after tax amounted to SEK 138.6m (88.0), corresponding to a loss per share before and after dilution of SEK 1.1 (0.9). The increased loss was primarily driven by increased investments in